Roche (VTX:ROG)‘s stock had its “buy” rating restated by analysts at Nord/LB in a report issued on Tuesday.

A number of other equities analysts have also weighed in on the stock. Credit Suisse Group set a CHF 260 price target on shares of Roche and gave the stock a “neutral” rating in a research report on Monday, October 16th. Baader Bank set a CHF 231 price target on shares of Roche and gave the stock a “neutral” rating in a research report on Thursday, October 19th. Morgan Stanley set a CHF 260 price target on shares of Roche and gave the stock a “neutral” rating in a research report on Friday, December 8th. set a CHF 210 price target on shares of Roche and gave the stock a “sell” rating in a research report on Monday, September 18th. Finally, Kepler Capital Markets set a CHF 230 price target on shares of Roche and gave the stock a “neutral” rating in a research report on Monday, September 11th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of CHF 262.89.

Shares of Roche (ROG) opened at CHF 251.10 on Tuesday. The company has a market cap of $216,540.00 and a PE ratio of 22.32. Roche has a one year low of CHF 226.10 and a one year high of CHF 273.

ILLEGAL ACTIVITY WARNING: “Roche (ROG) Stock Rating Reaffirmed by Nord/LB” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/roche-rog-stock-rating-reaffirmed-by-nordlb/1793573.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.